A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein
Latest Information Update: 27 Jun 2025
At a glance
- Drugs TOUR-006 (Primary)
- Indications Renal failure
- Focus Pharmacodynamics
- Acronyms TRANQUILITY
- Sponsors Tourmaline Bio
Most Recent Events
- 20 May 2025 According to a Tourmaline Bio media release, Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease and a planned Phase 2 proof-of-concept trial in abdominal aortic aneurysm.
- 20 May 2025 Primary endpoint has been met. (Evaluate the effects of TOUR006 compared with placebo on hs-CRP)
- 20 May 2025 Results published in the Media Release